Interest of a Systematic Assessment of the Treatment of LUTS in the Management of BPH (UROEVAL)

The frequency of patients with IPSS score <8 after three months of treatment with alpha-blockers is about 40%. The sample size required to detect a proportion of 40% with a precision of 0.04 is 550 patients. Based on a literature review of Lacoin et al, the frequency of treated patients with LUTS associated with BPH with an IPSS ≥ 8 is approximately 60%. Thus, 917 patients will be needed to obtain a sample of 550 patients with treatment of alpha-blockers (550/0.6 = 917).

Considering 10% of patients lost for follow-up or refusing treatment change, the total number required is estimated at about 1,000 patients.

Inclusion Criteria:

Patients aged 60 years or more suffering from LUTS/BPH AND medically treated for at least 6 months.

Exclusion Criteria:

• Patients with prostate cancer
• Patients requiring surgical treatment
• The absence of Lower Urinary Tract Symptoms
• Treatment initiation for less than 6 months
• Cognitive disorders or other pathologies leading to the inability to give its consent to the collection of data.
• Refusal to participate.